DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
ODM-201 is an investigational drug.
There have been 42 clinical trials for ODM-201. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Parkinson Disease, and Motor Neuron Disease. The leading clinical trial sponsors are Orion Corporation, Orion Pharma, Bayer, and University of Nottingham.
There are eight US patents protecting this investigational drug and eighty-four international patents.
Recent Clinical Trials for ODM-201
|Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)||Sir Mortimer B. Davis - Jewish General Hospital||Phase 2|
|Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer||Bayer||Phase 2|
|Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer||Prostate Cancer Canada||Phase 2|
Top disease conditions for ODM-201
Top clinical trial sponsors for ODM-201
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ODM-201||Start Trial||Carboxamide derivative and its diastereomers in stable crystalline form||Orlon Corporation (Espoo, FI)||Start Trial|
|ODM-201||Start Trial||Androgen receptor modulating compounds||ORION CORPORATION (Espoo, FI)||Start Trial|
|ODM-201||Start Trial||Process for the preparation of androgen receptor antagonists and intermediates thereof||Orion Corporation (Espoo, FI)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ODM-201||European Patent Office||3250554||2035-01-30||Start Trial|
|ODM-201||World Intellectual Property Organization (WIPO)||2016120530||2035-01-30||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|